Arcutis Biotherapeutics: Promising Biotech Upstart in Dermatological Therapy

Arcutis' value is almost entirely based on the approved non-steroidal medication ZORYVE® (Roflumilast), whose market expansion into indications such as atopic dermatitis holds annual peak revenue potential of over $2.5 billion. The company has positioned itself as an innovative provider of non-steroidal topical therapies, giving it a clear competitive advantage and ensuring long-term acceptance in chronic skin diseases. The company achieved profitability earlier than expected, forecasts revenue of $455-470 millio for 2026, and is continuously...